What exactly to make of PCR 'doubling' assets to $250B in an eye-blink...
Create a vendor selection project & run comparison reports
Click to express your interest in this report
Indication of coverage against your requirements
A subscription is required to activate this feature. Contact us for more info.
Celent have reviewed this profile and believe it to be accurate.
Will Trout: I find it hard to believe that PCR could attempt to replicate Addepar's attempts to map and aggregate the entire investments ecosystem. I'm skeptical of Addepar's progress already
Asia-Pacific, EMEA, LATAM, North America